Table 2.

Association of clinical and pathological variables with survival (cancer-specific survival)

Variable	Group	N	Median (minimum–maximum) (month)	95% CI	p
All		350	8 (1–138)	6.769–9.231
Sex					0.309
	Female	145	9 (1–112)	7.605–10.395
	Male	205	8 (1–138)	5.891–10.109
Race					0.866
	White	278	9 (1–138)	7.411–10.589
	Black	40	7 (1–36)	5.327–8.673
	Other	32	8 (1–92)	2.824–13.176
Age					0.012
	< 65y	191	9 (1–138)	7.592–10.408
	≥ 65y	159	6 (1–106)	4.208–7.792
Grade					0.177
	III	236	9 (1–138)	7.446–10.554
	IV	114	8 (1–76)	6.462–9.538
Tumor size					0.24
	< 2 cm	4	2 (2–28)	Undefined*
	2–4 cm	96	9 (1–92)	6.880–11.120
	> 4 cm	152	9 (1–138)	7.346–10.654
Tumor location					0.007
	Head	146	8 (1–68)	6.399–9.601
	Overlapping	31	9 (1–112)	7.121–10.879
	Body	28	9 (1–106)	2.912–15.088
	Tail	80	11 (1–138)	7.952–14.048
Lymph node metastases					0.729
	No	14	9 (1–60)	0.000–37.636
	Yes	46	11 (1–138)	7.032–14.968
Chemotherapy					0.007
	No	129	4 (1–138)	2.763–5.237
	Yes	221	10 (1–112)	8.841–11.159
Year of diagnosis					0.087
	< 2010	212	8 (1–138)	6.698–9.302
	≥ 2010	138	10 (1–50)	7.705–12.295
Primary site surgery					< 0.001
	Surgery performed	50	12 (1–138)	2.079–21.921
	Surgery not performed	300	8 (1–112)	6.594–9.406
	Recommended but not performed	38	9 (1–76)	6.123–11.877
	Not recommended and not performed	262	7 (1–112)	5.523–8.477
Site specific surgery					0.39
	Local or partial pancreatectomy	24	26 (2–50)	11.541–40.459
	Total pancreatectomy	4	8 (4–138)	0.000–95.547
	Whipple	19	11 (1–68)	8.525–13.475
	Unknown	3	9 (4–26)	0.998–17.002
Primary site surgery					0.216
	Primary site only	25	10 (3–68)	3.129–16.871
	Primary site and distant site	25	19 (1–138)	1.487–36.513
	Distant site only	10	8 (1–112)	4.901–11.099

^*Too small sample size and too different survival data of the patients might lead to the undefinition of the corresponding 95% CI